Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate
and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled …

Severe and poorly controlled asthma still accounts for a great portion of the patients affected.
Disease control and future risk management have been identified by international …

Introduction: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has
recently been approved for use in the treatment of asthma in a number of countries …

Background Recently published data support the benefits and safety of the once‐daily (OD)
long‐acting anticholinergic tiotropium bromide bronchodilator for the treatment of …

Background Data are limited on the differential response to long-acting bronchodilators in
older versus younger adults with asthma. Objective To determine whether the response to …

Purpose Chronic obstructive pulmonary disease (COPD) and asthma are leading causes of
morbidity and mortality. This narrative review provides an appraisal of the pharmacological …

A growing number of clinical trials are documenting that adding a long-acting muscarinic
antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and …

Asthma is the most common chronic disease in children. As suggested by international
guidelines, the main goals of asthma treatment are symptoms control and lung function …

Background Tiotropium, a long-acting anticholinergic bronchodilator, has demonstrated
efficacy and safety as add-on therapy to inhaled corticosteroids (ICS), with or without other …

Background: A Phase II trial has shown tiotropium Respimat®(tioR) to be a safe and well-
tolerated bronchodilator in patients aged 6-11 years with moderate symptomatic asthma …